Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc Wins U.S. Approval For New Flu Vaccine-Reuters


Monday, 17 Dec 2012 10:58am EST 

Reuters reported that U.S. health regulators have approved a new four strain seasonal influenza vaccine made by Glaxosmithkline Plc. The U.S. Food and Drug Administration has approved Fluarix Quadrivalent to immunize children age 3 and older and adults against flu virus subtypes A and B contained in the vaccine. Fluarix Quadrivalent helps protect against the two A strains and adds coverage against a second B strain. 

Latest Key Developments in Pharmaceuticals

Company Quote

19.704
-0.236 -1.18%
11 Jul 2014